ClinicalTrials.gg

Program

INR731

A development code.

Its studies are mostly in Prostatic Neoplasms, led by Novartis.

Furthest: phase 1, since Apr 30, 20261 company-led study, 1 open or runningNext primary completion: Jun 3, 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis11 open or runningphase 1since Apr 30, 2026Apr 30, 2026Jun 3, 2030phase 1 · NCT07570979
  • Named in Novartis’s own pipeline as INR731, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 30, 2026First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT07570979 · 208 planned · United States, Australia, Canada and more

Ahead

  1. Jun 3, 2030Primary completion: phase 1 study in Prostatic NeoplasmsNCT07570979

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07570979Prostatic Neoplasms · United States, Australia, Canada and more1RecruitingJun 3, 2030208

How it is read

Names in the registry

  • “INR731”, 1 entry

Codes read as this program: INR731.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.